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Eccrine porocarcinoma (EPC) is a rare skin
malignancy that represents around 0.01% of all skin
tumors.1,2 There is a wide range of clinical pre-
sentations of this neoplasm such as papules, plaques,
and nodules. Most tumors appear in the head and
neck region or on the lower extremities, but all body
parts can be involved. EPC is frequently clinically
misdiagnosed as squamous cell carcinoma or Bowen
disease because the tumors have similar clinical
presentations. Therefore, histopathologic examina-
tion prior to therapy is required.
EPC is known for its high recurrence and meta-
static rate of both 20%. Metastases are mostly found
in the regional lymph nodes and mortality among
patients with EPC with nodal metastasis is high
(67%). The survival period for patients with distant
metastasis is reported to be 5 to 24 months.1
At this moment, no therapy exists as the gold
standard because of the rarity of the disease,
although surgery (wide local excision or Mohs
micrographic surgery) is the common treatment for
local disease. In case of metastatic and/or recurrent
disease, it is suggested to add chemotherapy and/or
radiotherapy. There is no consistency about which
chemotherapy should be added due to the rarity of
the disease.1,2
Here we present a patient with EPC in situ with
lymph node metastases.
CASE REPORT
A 58-year-old man was referred by his general
practitioner to thedermatologyoutpatient clinic of ourDepartments of Dermatologya and Pathology,b Erasmus
ity Medical Center.
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oer@erasmusmc.nl.hospital with a skin lesion on his right hip. The lesion
existed for 11 years, and 2 previous biopsies per-
formed by the general practitioner both showed
Bowen disease. The lesion was subsequently repeat-
edly treated with cryotherapy without complete
response. A few weeks before his first visit to our
department, the lesion increased in size and thickness.
No other skin lesions were present and the medical
history was negative for any other skin disease.
Besides the skin lesion, 18 months earlier the
patient had biopsy-proven lymph node metastases
of the right groin, parailiac, and para-aortic right. The
lymph node biopsies showed a nonesmall cell
carcinoma of unknown primary origin. The tumor
cells were initially found positive for CKAE1/AE3,
CK7, EMA, GATA3, and p40, and negative staining
was found for SOX10, CD15, and OCT4. Based on
this immunohistochemical profile, the case was
signed out as a nonesmall cell carcinoma of un-
known primary origin. Based on the p401 and
GATA31 staining, a suggestion of metastatic poorly
differentiated squamous cell carcinoma or urothelial
carcinoma was made. Extensive clinical workup in
search for a primary tumor with computed tomog-
raphy, positron emission tomography, and cystos-
copy failed to detect a primary tumor. The patient
was subsequently treated with chemotherapy
(cisplatin-etoposide and carboplatin-etoposide).JAAD Case Reports 2020;6:42-5.
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Fig 1. Close-up of the lesion on the right hip of the patient.
Fig 2. Porocarcinoma in situ. A, The epidermis shows an intraepidermal proliferation of
expansile epithelial nests with cystic foci of ductal differentiation lined by an inner cuticle layer
and composed of poroid cells showing nuclear polymorphism and nuclear hyperchromasia. B,
EMA staining shows a positive inner EMA-positive cuticle layer on cystic foci of ductal
differentiation.
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we noticed an erythematous nummular superficial
plaque with central hyperkeratosis on the patient’s
right hip (Fig 1). No other skin lesions were seen.
A diagnostic excision of the whole lesion was
performed. Histopathologic examination found an
intraepidermal proliferation with large expansile
epithelial nests with central comedonecrosis. The
epithelial nests were composed of poroid cells
showing nuclear polymorphism and nuclear hyper-
chromasia. In areas, the proliferation showed cystic
foci of ductal differentiation with presence of an
inner EMA-positive cuticle layer (Fig 2, A and B).
Also, abortive duct differentiation was focally
observed in the form of intracytoplasmic lumina.
P53 showed an aberrantly high expression in le-
sional cells. Altogether, the histopathologic features
are consistent with eccrine porocarcinoma in situ.
Although invasive growth was not found, we
reasoned that the previously diagnosed lymphnode metastases could be metastases of the poro-
carcinoma in situ. Both the earlier biopsies of the
skin lesion and the earlier lymph node biopsies were
reviewed. In the skin biopsies, the diagnosis of a
porocarcinoma in situ was confirmed instead of the
previously diagnosed Bowen disease. Review of the
lymph node biopsies confirmed the metastases of a
nonesmall cell carcinoma. In retrospect, however,
the tumor cells in both biopsies focally showed
abortive duct differentiation with the presence of a
intracytoplasmic lumina (Fig 3, A). The luminal
cuticular layer was highlighted by epithelial mem-
brane antigen (EMA) staining that confirmed the
ductal differentiation (Fig 3, B). Additional molecular
analysis using targeted next-generation sequencing
of both the porocarcinoma in situ and the metastasis
found an identical hotspot TP53 exon 7 missense
mutation (c.743G[A,p.R248Q (NM 000546)) with a
variant allele frequency of 77% in the porocarcinoma
in situ and 17% in the lymph node metastasis
Fig 3. Lymph node metastasis shows fields of epithelial cells with cytonuclear atypia and focal




44 van den Brand et al(estimated tumor cell percentages 80% and 40%,
respectively). This hotspot mutation has previously
been identified in porocarcinoma; however, this
hotspot mutation is also commonly found in other
tumors.3 Single-nucleotide polymorphism analysis
showed loss of the wild-type TP53 allele in both
tumors. Furthermore, strong aberrant nuclear p53
immunohistochemical staining was present in both
lesions supporting our molecular findings.
Importantly, single-nucleotide polymorphism anal-
ysis identified additional chromosomal losses (chro-
mosome 3p, 10q, and 13q) that were shared by both
lesions.
Because of the similar histopathologic findings of
the porocarcinoma in situ and the lymph node
metastases, together with an identical molecular
profile, it is highly suggestive that both lesions
represent the same entity.
Unfortunately, the lymph node metastases pro-
gressed under chemotherapeutic treatment, and the
patient died of metastatic disease half a year after the
EPC in situ was diagnosed.DISCUSSION
There are several cases described in which an EPC
originated from the site of a pre-existing Bowen
disease.4-6 There are also cases described of lymph
node metastases with unknown primary tumor that
appeared to be metastasis of an eccrine porocarci-
noma.7 The uniqueness in this case is that the patient
was previously repeatedly given a diagnosis of
Bowen disease, which appeared to be a porocarci-
noma in situ and the primary tumor of lymph node
metastases. This case demonstrates the importance
of molecular analysis as a tool in search for the
primary tumor.
Several possibilities exist for how an in situ
carcinoma could cause lymph node metastases.
The primary tumor most likely regressed from
infiltrative to in situ from chemotherapy, aspreviously described in EPC.8 Another possibility is
that the innate or the adaptive immune system was
activated (upon metastasis) and caused spontaneous
regression of the invasive component of the primary
tumor.9,10 A third option is the chance that the
invasive component was sampled in the earlier
biopsies and/or the latter skin excision but not
detected by light microscopy, as not all tissue is
routinely analyzed. In case there was an invasive
component at that time, it could be gone as a result of
the previous treatments with cryotherapy.
Here we report a rare case of an eccrine
porocarcinoma in situ that metastasized to the
regional lymph nodes. We recommend to critically
re-assess the patient’s clinical history and findings
when there is a metastatic disease with an un-
known primary tumor and a superficial or in situ
lesion.
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